Enpro NPO Food and biopharmaceutical — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Enpro in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: Enpro’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enpro's food and biopharmaceutical — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enpro's food and biopharmaceutical — net sales?
- Enpro (NPO) reported food and biopharmaceutical — net sales of $19.08M in Q4 2025.
- How has Enpro's food and biopharmaceutical — net sales changed year-over-year?
- Enpro's food and biopharmaceutical — net sales increased by 12.7% year-over-year, from $16.93M to $19.08M.
- What is the long-term trend for Enpro's food and biopharmaceutical — net sales?
- Over 2 years (2023 to 2025), Enpro's food and biopharmaceutical — net sales has grown at a 8.0% compound annual growth rate (CAGR), from $65.4M to $76.3M.
- What does food and biopharmaceutical — net sales mean?
- The total revenue earned from products and services sold to the food and biopharmaceutical industries.
- How do you interpret food and biopharmaceutical — net sales?
- An increase indicates growing demand for the company's specialized solutions in these sectors, while a decrease may signal market saturation, loss of competitive edge, or reduced capital expenditure by clients in these industries.
- How does food and biopharmaceutical — net sales compare across companies?
- Comparable to segment-specific revenue reporting for industrial technology firms serving regulated end-markets, where peers typically report similar metrics to demonstrate diversification and specialized market exposure.